Nordion has announced that it is hosting an educational symposium: “The expanding role of radioembolization for the treatment of hepatocellular carcinoma.”
This will include the latest information about radioembolization, yttrium-90 (Y-90) glass microspheres in hepatocellular carcinoma and an update on phase III clinical trials. The symposium for referring physicians, including medical oncologists, hepatologists and gastroenterologists, is being held at this year’s Gastrointestinal Cancers Symposium in San Francisco, California, USA, from January 24–26, 2013.
The presentations are:
- “Y-90 glass microspheres in hepatocellular carcinoma—what do we know?” by Riad Salem, interventional oncologist, Northwestern University, Chicago, Illinois, USA. Salem will provide an overview of clinical utility of Y-90 glass microspheres including a review of the phase III clinical trial program for TheraSphere
- “TheraSphere vs. transarterial chemoembolization (TACE). Data Analysis in intermediate hepatocellular carcinoma—what did we learn?” by Lewis Roberts, gastroenterologist, Mayo Clinic, Rochester, Minnesota, USA. Roberts will present the results of a retrospective analysis of TheraSphere vs. TACE in patients with unresectable hepatocellular carcinoma
- “Prospective phase II study on intermediate and advanced hepatocellular carcinoma— experience at Milan, Italy”by Sherrie Bhoori, hepatologist, Istituto Tumori, Milan, Italy. Bhoori will discuss Istituto Tumori’s prospective phase II data published in hepatology and how this study led to the development of the phase III YES-P trial.
